M&A Deal Summary

Haitong International Zhonghua Finance Acquisition Fund I Acquires Obagi

On November 10, 2017, private equity firm Haitong International Zhonghua Finance Acquisition Fund I acquired consumer products company Obagi from Bausch Health for 190M USD

Acquisition Highlights
  • This is Haitong International Zhonghua Finance Acquisition Fund I’s 1st transaction in the Consumer Products sector.
  • This is Haitong International Zhonghua Finance Acquisition Fund I’s largest (disclosed) transaction.
  • This is Haitong International Zhonghua Finance Acquisition Fund I’s 1st transaction in the United States.
  • This is Haitong International Zhonghua Finance Acquisition Fund I’s 1st transaction in California.
Investment Fate
  • Obagi was sold to a publicly-traded strategic buyer in 2021.

M&A Deal Summary

Date 2017-11-10
Target Obagi
Sector Consumer Products
Buyer(s) Haitong International Zhonghua Finance Acquisition Fund I
Sellers(s) Bausch Health
Deal Type Divestiture
Deal Value 190M USD

Target

Obagi

Long Beach, California, United States
website
Obagi is a physician-dispensed brand in the dermo-cosmetic space, the highest-growth category in skin care. Obagi's product portfolio includes brands Obagi Nu-Derm®, Condition & Enhance®, Obagi-C® Rx, ELASTIDerm® and CLENZIDerm®.

Search 192,510 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

DESCRIPTION

Haitong International is a private equity firm that invests in a variety of industries and situations. Haitong International is headquartered in Hong Kong, China.


DEAL STATS #
Overall 1 of 1
Sector (Consumer Products) 1 of 1
Type (Divestiture) 1 of 1
State (California) 1 of 1
Country (United States) 1 of 1
Year (2017) 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-11-15 Obagi

Long Beach, California, United States

Obagi is a physician-dispensed brand in the dermo-cosmetic space, the highest-growth category in skin care. Obagi's product portfolio includes brands Obagi Nu-Derm®, Condition & Enhance®, Obagi-C® Rx, ELASTIDerm® and CLENZIDerm®.

Sell -

Seller(S) 1

SELLER

Bausch Health

Laval, Quebec, Canada

website


Category Company
Sector Life Science
Employees19,900
Revenue 8.1B USD (2022)
DESCRIPTION

Bausch Health is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology, and branded generics. Bausch Health is based in Laval, Quebec.


DEAL STATS #
Overall 9 of 10
Sector (Consumer Products) 5 of 5
Type (Divestiture) 9 of 10
State (California) 2 of 2
Country (United States) 7 of 7
Year (2017) 6 of 6
Size (of disclosed) 4 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-06-08 iNova Pharmaceuticals

Chatswood, Australia

iNova Pharmaceuticals is a developer and marketer of over-the-counter and prescription medicines. iNova Pharmaceuticals was founded in 1958 and is based in Chatswood, Australia.

Sell $930M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-02-26 Synergy Pharmaceuticals - Certain Assets

New York, New York, United States

Synergy Pharmaceuticals, Inc. - Certain Assets includes TRULANCE (plecanatide), a once-daily tablet approved for adults with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), and its investigational compound, dolcanatide, is an incremental peptide with established proof-of-concept studies in multiple GI conditions.

Buy $195M